Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study

Background: Both pemafibrate and sodium glucose cotransporter-2 (SGLT2) inhibitor can decrease serum transaminase levels in patients with non-alcoholic fatty liver disease (NAFLD) complicated with dyslipidemia and type 2 diabetes mellitus (T2DM), respectively. However, the effectiveness of combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozaki, Satoshi, Tahara, Toshiyuki, Miura, Kouichi, Lefor, Alan Kawarai, Yamamoto, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302975/
https://www.ncbi.nlm.nih.gov/pubmed/37374110
http://dx.doi.org/10.3390/life13061327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302975/
https://www.ncbi.nlm.nih.gov/pubmed/37374110
http://dx.doi.org/10.3390/life13061327

Ejemplares similares